Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
GAITHERSBURG, Md., May 02, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.
Conference call details are as follows:
| Date: | May 9, 2018 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 9, 2018 until | |
| 7:30 p.m. ET May 16, 2018 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until August 9, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.
Contact:
Investors
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
